Hereditary colorectal cancer syndromes: American society of clinical oncology clinical practice guideline endorsement of familial risk-colorectal cancer: European Society for medical oncology clinical practice guidelines

Elena M. Stoffel, Pamela B. Mangu, Stephen B. Gruber, Stanley R. Hamilton, Matthew F. Kalady, Michelle Wan Yee Lau, Karen H. Lu, Nancy Roach, Paul John Limburg

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

Purpose To provide recommendations on prevention, screening, genetics, treatment, and management for people at risk for hereditary colorectal cancer (CRC) syndromes. The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. Methods The Familial Risk-Colorectal Cancer: European Society for Medical Oncology Clinical Practice Guideline published in 2013 on behalf of the European Society for Medical Oncology (ESMO) Guidelines Working Group in Annals of Oncology was reviewed for developmental rigor by methodologists, with content and recommendations reviewed by an ASCO endorsement panel. Results The ASCO endorsement panel determined that the recommendations of the ESMO guidelines are clear, thorough, and based on the most relevant scientific evidence. The ASCO panel endorsed the ESMO guidelines and added a few qualifying statements. Recommendations Approximately 5% to 6% of patient cases of CRC are associated with germline mutations that confer an inherited predisposition for cancer. The possibility of a hereditary cancer syndrome should be assessed for every patient at the time of CRC diagnosis. A diagnosis of Lynch syndrome, familial adenomatous polyposis, or another genetic syndrome can influence clinical management for patients with CRC and their family members. Screening for hereditary cancer syndromes in patients with CRC should include review of personal and family histories and testing of tumors for DNA mismatch repair deficiency and/or microsatellite instability. Formal genetic evaluation is recommended for individuals who meet defined criteria.

Original languageEnglish (US)
Pages (from-to)209-217
Number of pages9
JournalJournal of Clinical Oncology
Volume33
Issue number2
DOIs
StatePublished - Oct 10 2015

Fingerprint

Hereditary Neoplastic Syndromes
Medical Oncology
Practice Guidelines
Colorectal Neoplasms
Guidelines
DNA Repair-Deficiency Disorders
Hereditary Nonpolyposis Colorectal Neoplasms
Microsatellite Instability
Adenomatous Polyposis Coli
DNA Mismatch Repair
Germ-Line Mutation
Genetic Testing
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Hereditary colorectal cancer syndromes : American society of clinical oncology clinical practice guideline endorsement of familial risk-colorectal cancer: European Society for medical oncology clinical practice guidelines. / Stoffel, Elena M.; Mangu, Pamela B.; Gruber, Stephen B.; Hamilton, Stanley R.; Kalady, Matthew F.; Lau, Michelle Wan Yee; Lu, Karen H.; Roach, Nancy; Limburg, Paul John.

In: Journal of Clinical Oncology, Vol. 33, No. 2, 10.10.2015, p. 209-217.

Research output: Contribution to journalArticle

Stoffel, Elena M. ; Mangu, Pamela B. ; Gruber, Stephen B. ; Hamilton, Stanley R. ; Kalady, Matthew F. ; Lau, Michelle Wan Yee ; Lu, Karen H. ; Roach, Nancy ; Limburg, Paul John. / Hereditary colorectal cancer syndromes : American society of clinical oncology clinical practice guideline endorsement of familial risk-colorectal cancer: European Society for medical oncology clinical practice guidelines. In: Journal of Clinical Oncology. 2015 ; Vol. 33, No. 2. pp. 209-217.
@article{ad34e09ea31e471e8754b96b3eb91ee2,
title = "Hereditary colorectal cancer syndromes: American society of clinical oncology clinical practice guideline endorsement of familial risk-colorectal cancer: European Society for medical oncology clinical practice guidelines",
abstract = "Purpose To provide recommendations on prevention, screening, genetics, treatment, and management for people at risk for hereditary colorectal cancer (CRC) syndromes. The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. Methods The Familial Risk-Colorectal Cancer: European Society for Medical Oncology Clinical Practice Guideline published in 2013 on behalf of the European Society for Medical Oncology (ESMO) Guidelines Working Group in Annals of Oncology was reviewed for developmental rigor by methodologists, with content and recommendations reviewed by an ASCO endorsement panel. Results The ASCO endorsement panel determined that the recommendations of the ESMO guidelines are clear, thorough, and based on the most relevant scientific evidence. The ASCO panel endorsed the ESMO guidelines and added a few qualifying statements. Recommendations Approximately 5{\%} to 6{\%} of patient cases of CRC are associated with germline mutations that confer an inherited predisposition for cancer. The possibility of a hereditary cancer syndrome should be assessed for every patient at the time of CRC diagnosis. A diagnosis of Lynch syndrome, familial adenomatous polyposis, or another genetic syndrome can influence clinical management for patients with CRC and their family members. Screening for hereditary cancer syndromes in patients with CRC should include review of personal and family histories and testing of tumors for DNA mismatch repair deficiency and/or microsatellite instability. Formal genetic evaluation is recommended for individuals who meet defined criteria.",
author = "Stoffel, {Elena M.} and Mangu, {Pamela B.} and Gruber, {Stephen B.} and Hamilton, {Stanley R.} and Kalady, {Matthew F.} and Lau, {Michelle Wan Yee} and Lu, {Karen H.} and Nancy Roach and Limburg, {Paul John}",
year = "2015",
month = "10",
day = "10",
doi = "10.1200/JCO.2014.58.1322",
language = "English (US)",
volume = "33",
pages = "209--217",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Hereditary colorectal cancer syndromes

T2 - American society of clinical oncology clinical practice guideline endorsement of familial risk-colorectal cancer: European Society for medical oncology clinical practice guidelines

AU - Stoffel, Elena M.

AU - Mangu, Pamela B.

AU - Gruber, Stephen B.

AU - Hamilton, Stanley R.

AU - Kalady, Matthew F.

AU - Lau, Michelle Wan Yee

AU - Lu, Karen H.

AU - Roach, Nancy

AU - Limburg, Paul John

PY - 2015/10/10

Y1 - 2015/10/10

N2 - Purpose To provide recommendations on prevention, screening, genetics, treatment, and management for people at risk for hereditary colorectal cancer (CRC) syndromes. The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. Methods The Familial Risk-Colorectal Cancer: European Society for Medical Oncology Clinical Practice Guideline published in 2013 on behalf of the European Society for Medical Oncology (ESMO) Guidelines Working Group in Annals of Oncology was reviewed for developmental rigor by methodologists, with content and recommendations reviewed by an ASCO endorsement panel. Results The ASCO endorsement panel determined that the recommendations of the ESMO guidelines are clear, thorough, and based on the most relevant scientific evidence. The ASCO panel endorsed the ESMO guidelines and added a few qualifying statements. Recommendations Approximately 5% to 6% of patient cases of CRC are associated with germline mutations that confer an inherited predisposition for cancer. The possibility of a hereditary cancer syndrome should be assessed for every patient at the time of CRC diagnosis. A diagnosis of Lynch syndrome, familial adenomatous polyposis, or another genetic syndrome can influence clinical management for patients with CRC and their family members. Screening for hereditary cancer syndromes in patients with CRC should include review of personal and family histories and testing of tumors for DNA mismatch repair deficiency and/or microsatellite instability. Formal genetic evaluation is recommended for individuals who meet defined criteria.

AB - Purpose To provide recommendations on prevention, screening, genetics, treatment, and management for people at risk for hereditary colorectal cancer (CRC) syndromes. The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. Methods The Familial Risk-Colorectal Cancer: European Society for Medical Oncology Clinical Practice Guideline published in 2013 on behalf of the European Society for Medical Oncology (ESMO) Guidelines Working Group in Annals of Oncology was reviewed for developmental rigor by methodologists, with content and recommendations reviewed by an ASCO endorsement panel. Results The ASCO endorsement panel determined that the recommendations of the ESMO guidelines are clear, thorough, and based on the most relevant scientific evidence. The ASCO panel endorsed the ESMO guidelines and added a few qualifying statements. Recommendations Approximately 5% to 6% of patient cases of CRC are associated with germline mutations that confer an inherited predisposition for cancer. The possibility of a hereditary cancer syndrome should be assessed for every patient at the time of CRC diagnosis. A diagnosis of Lynch syndrome, familial adenomatous polyposis, or another genetic syndrome can influence clinical management for patients with CRC and their family members. Screening for hereditary cancer syndromes in patients with CRC should include review of personal and family histories and testing of tumors for DNA mismatch repair deficiency and/or microsatellite instability. Formal genetic evaluation is recommended for individuals who meet defined criteria.

UR - http://www.scopus.com/inward/record.url?scp=84920943765&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920943765&partnerID=8YFLogxK

U2 - 10.1200/JCO.2014.58.1322

DO - 10.1200/JCO.2014.58.1322

M3 - Article

C2 - 25452455

AN - SCOPUS:84920943765

VL - 33

SP - 209

EP - 217

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -